Challenge of creating single-agents for the treatment of type 1 and 2 diabetes by targeting retinoid X receptor

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

It might be seen as reckless to challenge to create single-agents for the treatment of both type 1 diabetes caused by the destruction of the Langerhans β cells in pancreas by excessive autoimmunity, and type 2 diabetes caused by the obesity. However, we hypothesized that retinoid X receptor (RXR) agonists, which are researched for the treatment of type 2 diabetes, will also be useful like metformin, which shows insulin-sparing effect in type 1 diabetes. This is because PPARg /RXR is known to be a target of thiazolidinediones (TZDs), which are used for the treatment of insulin resistance, LXR /RXR is reported to be involved in glucose/lipid metabolism, and these heterodimers can be activated by RXR agonists alone (permissive mechanism). However, repeated administration of RXR agonists can elevate blood triglyceride and induce hypothyroidism. In this study, we performed systematic conversion of the alkoxy side chain of 5a (6-[ethyl-(3- isopropoxy-4-isopropylphenyl)amino] nicotinic acid: NEt-3IP) and evaluated the RXR-, PPAR/RXR- and LXR/ RXR-agonist activities of the products. The cyclopropylmethoxy analog (5c) showed similar RXR- and LXR/RXRagonistic activities to the benzyloxy analog (5i) and n-propoxy analog (5k), but exhibited more potent PPAR/RXRagonistic activity than 5i or 5k. DiŠerential modulation of RXR heterodimer-activating ability by conversion of the alkoxy group located in the lipophilic domain of the RXR-agonist common structure is expected to be a useful approach in the design of new RXR agonists for the treatment of hyperlipidemia.

Original languageEnglish
Pages (from-to)917-923
Number of pages7
JournalYakugaku Zasshi
Volume131
Issue number6
DOIs
Publication statusPublished - 2011

Fingerprint

Retinoid X Receptors
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Peroxisome Proliferator-Activated Receptors
Thiazolidinediones
Langerhans Cells
Niacin
Metformin
Hypothyroidism
Hyperlipidemias
Autoimmunity
Lipid Metabolism
Insulin Resistance
Pancreas
Triglycerides

Keywords

  • Diabetes mellitus
  • Retinoid X receptor (RXR)
  • RXR-permissive heterodimer
  • Type 1 diabetes
  • Type 2 diabetes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Challenge of creating single-agents for the treatment of type 1 and 2 diabetes by targeting retinoid X receptor. / Kakuta, Hiroki.

In: Yakugaku Zasshi, Vol. 131, No. 6, 2011, p. 917-923.

Research output: Contribution to journalArticle

@article{73bc8e846f914fb188b5304d33f51d49,
title = "Challenge of creating single-agents for the treatment of type 1 and 2 diabetes by targeting retinoid X receptor",
abstract = "It might be seen as reckless to challenge to create single-agents for the treatment of both type 1 diabetes caused by the destruction of the Langerhans β cells in pancreas by excessive autoimmunity, and type 2 diabetes caused by the obesity. However, we hypothesized that retinoid X receptor (RXR) agonists, which are researched for the treatment of type 2 diabetes, will also be useful like metformin, which shows insulin-sparing effect in type 1 diabetes. This is because PPARg /RXR is known to be a target of thiazolidinediones (TZDs), which are used for the treatment of insulin resistance, LXR /RXR is reported to be involved in glucose/lipid metabolism, and these heterodimers can be activated by RXR agonists alone (permissive mechanism). However, repeated administration of RXR agonists can elevate blood triglyceride and induce hypothyroidism. In this study, we performed systematic conversion of the alkoxy side chain of 5a (6-[ethyl-(3- isopropoxy-4-isopropylphenyl)amino] nicotinic acid: NEt-3IP) and evaluated the RXR-, PPAR/RXR- and LXR/ RXR-agonist activities of the products. The cyclopropylmethoxy analog (5c) showed similar RXR- and LXR/RXRagonistic activities to the benzyloxy analog (5i) and n-propoxy analog (5k), but exhibited more potent PPAR/RXRagonistic activity than 5i or 5k. DiŠerential modulation of RXR heterodimer-activating ability by conversion of the alkoxy group located in the lipophilic domain of the RXR-agonist common structure is expected to be a useful approach in the design of new RXR agonists for the treatment of hyperlipidemia.",
keywords = "Diabetes mellitus, Retinoid X receptor (RXR), RXR-permissive heterodimer, Type 1 diabetes, Type 2 diabetes",
author = "Hiroki Kakuta",
year = "2011",
doi = "10.1248/yakushi.131.917",
language = "English",
volume = "131",
pages = "917--923",
journal = "Yakugaku Zasshi",
issn = "0031-6903",
publisher = "Pharmaceutical Society of Japan",
number = "6",

}

TY - JOUR

T1 - Challenge of creating single-agents for the treatment of type 1 and 2 diabetes by targeting retinoid X receptor

AU - Kakuta, Hiroki

PY - 2011

Y1 - 2011

N2 - It might be seen as reckless to challenge to create single-agents for the treatment of both type 1 diabetes caused by the destruction of the Langerhans β cells in pancreas by excessive autoimmunity, and type 2 diabetes caused by the obesity. However, we hypothesized that retinoid X receptor (RXR) agonists, which are researched for the treatment of type 2 diabetes, will also be useful like metformin, which shows insulin-sparing effect in type 1 diabetes. This is because PPARg /RXR is known to be a target of thiazolidinediones (TZDs), which are used for the treatment of insulin resistance, LXR /RXR is reported to be involved in glucose/lipid metabolism, and these heterodimers can be activated by RXR agonists alone (permissive mechanism). However, repeated administration of RXR agonists can elevate blood triglyceride and induce hypothyroidism. In this study, we performed systematic conversion of the alkoxy side chain of 5a (6-[ethyl-(3- isopropoxy-4-isopropylphenyl)amino] nicotinic acid: NEt-3IP) and evaluated the RXR-, PPAR/RXR- and LXR/ RXR-agonist activities of the products. The cyclopropylmethoxy analog (5c) showed similar RXR- and LXR/RXRagonistic activities to the benzyloxy analog (5i) and n-propoxy analog (5k), but exhibited more potent PPAR/RXRagonistic activity than 5i or 5k. DiŠerential modulation of RXR heterodimer-activating ability by conversion of the alkoxy group located in the lipophilic domain of the RXR-agonist common structure is expected to be a useful approach in the design of new RXR agonists for the treatment of hyperlipidemia.

AB - It might be seen as reckless to challenge to create single-agents for the treatment of both type 1 diabetes caused by the destruction of the Langerhans β cells in pancreas by excessive autoimmunity, and type 2 diabetes caused by the obesity. However, we hypothesized that retinoid X receptor (RXR) agonists, which are researched for the treatment of type 2 diabetes, will also be useful like metformin, which shows insulin-sparing effect in type 1 diabetes. This is because PPARg /RXR is known to be a target of thiazolidinediones (TZDs), which are used for the treatment of insulin resistance, LXR /RXR is reported to be involved in glucose/lipid metabolism, and these heterodimers can be activated by RXR agonists alone (permissive mechanism). However, repeated administration of RXR agonists can elevate blood triglyceride and induce hypothyroidism. In this study, we performed systematic conversion of the alkoxy side chain of 5a (6-[ethyl-(3- isopropoxy-4-isopropylphenyl)amino] nicotinic acid: NEt-3IP) and evaluated the RXR-, PPAR/RXR- and LXR/ RXR-agonist activities of the products. The cyclopropylmethoxy analog (5c) showed similar RXR- and LXR/RXRagonistic activities to the benzyloxy analog (5i) and n-propoxy analog (5k), but exhibited more potent PPAR/RXRagonistic activity than 5i or 5k. DiŠerential modulation of RXR heterodimer-activating ability by conversion of the alkoxy group located in the lipophilic domain of the RXR-agonist common structure is expected to be a useful approach in the design of new RXR agonists for the treatment of hyperlipidemia.

KW - Diabetes mellitus

KW - Retinoid X receptor (RXR)

KW - RXR-permissive heterodimer

KW - Type 1 diabetes

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=79958043788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958043788&partnerID=8YFLogxK

U2 - 10.1248/yakushi.131.917

DO - 10.1248/yakushi.131.917

M3 - Article

VL - 131

SP - 917

EP - 923

JO - Yakugaku Zasshi

JF - Yakugaku Zasshi

SN - 0031-6903

IS - 6

ER -